Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice

Immunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer while...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dong-qun, Lu, Shuai, Zhang, Lun, Huang, Ya-ru, Ji, Mei, Sun, Xiao-ying, Liu, Xiao-ge, Liu, Rui-tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563250/
https://www.ncbi.nlm.nih.gov/pubmed/32630299
http://dx.doi.org/10.3390/vaccines8030351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563250/
https://www.ncbi.nlm.nih.gov/pubmed/32630299
http://dx.doi.org/10.3390/vaccines8030351

Ejemplares similares